TABLE 1.

Characteristics of subjects studied

Patient and/or group parameteraGenderViral genotypeVLbNo. of cells/μlcHLA haplotypeEstimated time from infection (no. of days)d
vpunefNo. of RNA copies/mlLog10 VLCD4+CD8+HLA-A allele(s)HLA-B allele(s)
B patients
    B1FemaleBB>500,000>5.74161,90024, 2635, 3543120
    B2MaleBB>500,000>5.79815,8862, 244, 35156
    B3MaleBB23,7634.384517583, 2613, 3895
    B4MaleBB9,7013.993737132, 3257, 4445
    B5MaleBB41,1344.6136456911, 2444, 3568
    B6MaleBB151,6625.184391,6022, 344, 45145
    B7MaleBB19,2894.294971,7662, 3140, 35170
    B8MaleBB46,7624.674656302, 3251, 3532
    B9MaleBB19,1334.2828658653, 297, 3920
B patient parameters
    IQ2519,2114.28393.8735
    Median41,1344.614391,184
    IQ75325,8315.446811,832
BF patients
    BF1MaleBFF32,3894.513087701, 235, 7120
    BF2MaleBFF>500,000>5.73061,1523, 247, 5020
    BF3MaleBFF>500,000>5.72432,0791, 6849, 4960
    BF4FemaleBFF36,6684.566127742, 37, 44135
    BF5MaleFF>500,000>5.72091,2292, 3140, 35152
    BF6FemaleBFF55,2794.7456899923, 66/2658, 4145
    BF7MaleBFF>500,000>5.72273852, 2435, 3535
BF patient parameters
    IQ2536,6684.56227770
    Median>500,0005.7306999
    IQ75>500,0005.75681,229
Nonprogressors
    NP1FemaleBB<50<1.71,0938641, 3135, 57>10 yr
    NP2MaleBB1,1123.0467083692, 315, 7>10 yr
  • a For the B and BF patient groups, the median and 25% and 75% interquartile values (IQ25 and IQ75, respectively) for VL, log10 VL, CD4 count, and CD8 count are shown. The differences observed between the values for both groups for VL (P = 0.142), log10 VL (P = 0.146), CD4 count (P = 0.071), and CD8 count (P = 0.6) were not statistically significant.

  • b Viral load (VL) calculated by the Versant HIV-1 RNA 3.0 assay (Bayer AG). The detection threshold was 50 RNA copies/ml (1.7 log10).

  • c Flow cytometry double platform (Epics XL; Coulter).

  • d The estimated time from infection is shown in days unless specified otherwise.